Inhibikase Therapeutics
IKT
74 hedge funds and large institutions have $218M invested in Inhibikase Therapeutics in 2025 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 27 increasing their positions, 15 reducing their positions, and 1 closing their positions.
2,000% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 1
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
145% more capital invested
Capital invested by funds: $89M → $218M (+$129M)
80% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 15
69.05% more ownership
Funds ownership: 73.76% → 142.81% (+69%)
37% more funds holding
Funds holding: 54 → 74 (+20)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$9.31M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$7.24M |
| 3 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$6.14M |
| 4 |
Blackstone Inc
New York
|
+$5.25M |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$4.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$82.1K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$77K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$66.4K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$40.7K |
| 5 |
JP Morgan Chase
New York
|
-$39.9K |
IKT Hedge Fund Activity: Q4 2025 in Review
74 of the 8,275 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q4 2025, worth a combined $218M — up 145% from $89M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new IKT positions and 1 closed out — a net gain of 20 holders — while 27 added to existing stakes and 15 trimmed.
The largest buyer was Siren LLC, opening a new position worth an estimated $9.31M. The largest seller was Northern Trust, cutting an estimated $82.1K.
- 74 institutional investors held Inhibikase Therapeutics (IKT) as of Q4 2025, up from 54 in Q3 2025.
- Funds reported $218M of Inhibikase Therapeutics stock for Q4 2025, up 145% quarter-over-quarter.
- 21 funds opened new Inhibikase Therapeutics positions in Q4 2025 and 1 closed out, a net change of +20 holders.
- The largest Inhibikase Therapeutics buyer in Q4 2025 was Siren LLC, an estimated $9.31M added.
- The largest Inhibikase Therapeutics seller in Q4 2025 was Northern Trust, an estimated $82.1K sold.
Based on aggregated 13F filings for Q4 2025.